Venom immunotherapy. Side effects and efficacy of treatment;Insektengifthyposensibilisierung. Nebenwirkungen und therapieerfolg

Hautarzt

Volumn 59, Issue 3, 2008, Pages 200-205

  Rueff F ^a   Przybilla, B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anaphylaxis; Efficacy; Hymenoptera venom allergy; Side effects; Venom immunotherapy

Indexed keywords

ANTIHISTAMINIC AGENT; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYMENOPTERA VENOM;

ALLERGY; ANAPHYLAXIS; DESENSITIZATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYMENOPTERA VENOM ALLERGY; IMMUNOTHERAPY; MASTOCYTOSIS; PROPHYLAXIS; REVIEW; RISK FACTOR; TREATMENT FAILURE;

ANAPHYLAXIS; ANIMALS; BEE VENOMS; HUMANS; IMMUNOTHERAPY; INSECT BITES AND STINGS; WASP VENOMS;

EID: 40549097732     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-008-1470-x     Document Type: Review

References (50)

1. Arzneimittelkommision der Deutschen Ärzteschaft (1994) Anaphylaktoide Reaktionen bei Patienten mit ACE-Hemmer-Behandlung bei gleichzeitiger Desensibilisierungsbehandlung oder nach Insektenstichen. Arzneimittel-Schnellinformation des Bundesinstitutes für Arzneimittel und Medizinprodukte. Dtsch Ärzteblatt 91: B-1762
2. Birnbaum J, Charpin D, Vervloet D (1993) Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 23: 226-230
3. Birnbaum J, Ramadour M, Magnan A, Vervloet D (2003) Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 33: 58-64
4. Bonifazi F, Jutel M, Biló BM et al. (2005) Prevention and treatment of Hymenoptera venom allergy: guidelines for clinical practice. Allergy 60: 1459-1470
5. Bousquet J, Lockey R, Malling HJ (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102: 558-562
6. Brehler R, Wolf H, Kutting B et al. (2000) Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 105: 1231-1235
7. Brockow K, Kiehn M, Riethmuller C et al. (1997) Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 100: 458-463
8. Erdmann SM, Sachs B, Kwiecien R et al. (2004) The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. Allergy 59: 1102-1109
9. Gastaminza G, Algorta J, Audicana M et al. (2003) Systemic reactions to immunotherapy: influence of composition and manufacturer. Clin Exp Allergy 33: 470-474
10. Goldberg A, Confino-Cohen R (2003) Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 91: 405-410
11. Golden DBK, Kagey-Sobotka A, Valentine MD, Lichtenstein LM (1981) Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 67: 370-374
12. Golden DBK, Kwiterovich KA, Kagey-Sobotka A et al. (1996) Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 97: 579-587
13. Haeberli G, Bronnimann M, Hunziker T, Müller U (2003) Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 33: 1216-1220
14. Haugaard L, Nørregaard OFH, Dahl R (1991) In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 87: 699-702
15. Hipler U-C, Bauer A, Schlenvoigt G, Elsner P (2001) Untersuchungen zur Verlaufskontrolle der Hyposensibilisierung mit Hilfe des Zellantigenstimulationstests (CAST). Allergologie 24: 9-13
16. Hunt KJ, Valentine MD, Sobotka AK et al. (1978) A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 299: 157-161
17. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW (1991) Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 88: 339-348
18. Laurent J, Smiejan JM, Bloch-Morot E, Herman D (1997) Safety of Hymenoptera venom rush immunotherapy. Allergy 52: 94-96
19. Lee H-H, Landeck L, Stefaniak R et al. (2005) Verträglichkeit der spezifischen Wespengift-Immuntherapie nach einem Rush- oder Ultra-Rush- Protokoll. Allergo J 14: 482-486
20. Mellerup MT, Hahn GW, Poulsen LK, Malling H (2000) Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 30: 1423-1429
21. Mokry L, Wüthrich B, Dietschi R (1985) Zur kausalen Behandlung der Hymenopterenstichallergie. Schweiz Rundschau Med 38: 1005-1016
22. Mosbech H, Malling H-J, Biering I et al. (1986) Immunotherapy with yellow jacket venom. Allergy 41: 95-103
23. Mosbech H, Müller U (2000) Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 55: 1005-1010
24. Müller U, Berchtold E, Helbling A (1991) Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 87: 702-709
25. Müller U, Helbling A, Berchtold E (1992) Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 89: 529-535
26. Müller UR (2003) Fatal course of Vespula venom immunotherapy: pretreatment withdrawal of the beta-blocker may have been involved. Allergy 58 (Suppl 74): 99-100
27. Müller UR, Haeberli G (2005) Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 115: 606-610
28. Müller UR (2008) Hautarzt, Hymenopterengift - Anaphylaxie und Herz-Kreislauf-Erkrankungen, Band 059. (Veröffentlichung in diesem Heft)
29. Oude Elberink JNG, de Monchy JGR, Kors JW et al. (1997) Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 99: 153-154
30. Przybilla B, Ring J, Grießhammer B, Braun-Falco O (1987) Schnellhyposensibilisierung mit Hymenopterengiften. Verträglichkeit und Therapieerfolg. Dtsch Med Wochenschr 112: 416-424
31. Przybilla B, Ruëff F, Fuchs T et al. (2004) Insektengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J 13: 186-190
32. Przybilla B, Müller U, Jarisch R, Ruëff F (2004) Erhöhte basale Serumtryptasekonzentration oder Mastozytose als Risikofaktor der Hymenopterengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J 13: 440-442
33. Quercia O, Rafanelli S, Puccinelli P, Stefanini GF (2001) The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. J Investig Allergol Clin Immunol 11: 27-33
34. Reimers A, Hari Y, Muller U (2000) Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 55: 484-488
35. Rerinck HC, Przybilla B, Ruëff F (2007) Wiederholte anaphylaktische Reaktionen bei Bienengifthyposensibilisierung: Gute Verträglichkeit nach Omalizumabgabe. Allergo J 16: S95-96
36. Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P (2006) Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 16: 79-85
37. Roy SR, Sigmon JR, Olivier J et al. (2007) Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 99: 82-86
38. Ruëff F, Przybilla B, Müller U, Mosbech H (1996) The sting challenge test in Hymenoptera venom allergy. Allergy 51: 216-225
39. Ruëff F, Wenderoth A, Przybilla B (2001) Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108: 1027-1032
40. Ruëff F, Ludolph-Hauser D, Przybilla B (2003) Erhöhte basale Serumtryptrase als Risikofaktor der Insektengiftallergie. Allergo J 12: S32-S38
41. Ruëff F, Wolf H, Schnitker J et al. (2004) Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 59: 589-595
42. Ruëff F, Bauer C, Albert K, Przybilla B (2005) Mastocytosis is a stronger risk factor for treatment failure of Hymenoptera venom immunotherapy than elevated baseline serum tryptase. Allergy Clin Immunol Int - J WAO Org 17 (Suppl 1): 6
43. Schiavino D, Nucera E, Pollastrini E et al. (2004) Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 92: 409-413
44. Schulze J, Rose M, Zielen S (2007) Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 62: 963-964
45. Steiss JO, Jödicke B, Lindemann H (2006) A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc 27: 148-50
46. Sturm G, Kranke B, Rudolph C, Aberer W (2002) Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 110: 928-933
47. Urbanek R, Forster J, Kuhn W, Ziupa J (1985) Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 107: 367-371
48. Van Halteren HK, van der Linden P-WG, Burgers JA, Bartelink AKM (1997) Discontinuation of yellow jacket venom immunotherapy: Follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 100: 767-770
49. Wieczorek D, Kapp A, Wedi B (2005) Omalizumab ermöglicht Einleitung einer Hyposensibilisierungsbehandlung mit Bienengift bei Risikopatient mit erhöhter Serumtryptase. Allergo J 14: 515
50. Wenzel J, Meissner-Kraemer M, Bauer R et al. (2003) Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy 58: 1176-1179